Brain Tumor Related News!
Fundraisers For Brain Tumor Research!
Brain Tumor Conferences / Events
New Clinical Trials
Noteworthy Treatments Explanation of the new high tech treatments!
Conferences / Events
- No events scheduled. Please check back soon!
Brain Tumor News!
Displaying Stories 1 to 20 of 6,086
01/19/17 Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
That is amazing, as doctors have to take a course to get certified in the use of Optune. This means that practically every major brain tumor center in the USA can offer Optune to their patients. There was a 70 percent increase in the survival rate at 4 years for newly diagnosed GBM patients, and Optune is now considered the standard of care for newly diagnosed gbms!
01/19/17 Musella Foundation Copayment Assistance Program is now closed to new patients
We are officially closed to new patients, but if you need assistance - send in the application anyway by tomorrow (Friday 1/20/17). We have a few pending applications waiting for more info. If they are not approved, we will be able to process a few more. I can't promise they will get funded - but I will try my best.
Amazing how many people need help. I feel bad that we can't help them all.
01/19/17 Glioblastoma Treatment Breakthrough: 'Untreatable' Brain Cancer Tumor Stabilized With Malaria Drug
Chloroquine is a cheap drug approved for treatment of Malaria, and is now being tested against many types of cancer. This article talks about success with 3 patients, and all 3 benefitted. In our brain tumor virtual trial registry, we have 8 patients who tried it. 5 out of the 8 lived over 2 years, and 3 went on to become long term survivors. Note that they also took many other treatments besides Chloroquine, so it is impossible for us to tell if it was due to the Chloroquine, but it may be worth looking at closely
01/15/17 Immunotherapies for GBM: Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A.
This is a video about the DCVax trial, given by one of my all time favorite brain tumor doctors, Dr. Liau. This looks very promising. We are hoping to hear the results of the big phase 3 trial soon.
In the earlier trials and in the early progressors which were excluded from this trial but were followed as they took the vaccine, about 25% of the patients went on to be long term survivors, with many alive and progression free 5-10 years later. That is unheard of with the standard treatments. Some other immunotherapies have also reported similiar results (although not as long follow up). We are hoping this large phase 3 trial shows something close to that so it can be approved quickly and all patients can benefit from it. Best of all it had no serious side effects.
Dr. Liau is on the Musella Foundation Medical Advisory Board. The Musella Foundation has supported Dr Liau's immunotherapy research with $375,000 in grants and we have never received any financial support from the company developing this treatment, Northwest Biotherapeutics.
01/14/17 National Walk To End Brain Tumors – Volunteers needed
We desperately need to fund more brain tumor research. We have many research proposals on our desk that are just waiting to be funded. Any of them might lead to advances. If you have the energy - please volunteer. (And when the time comes - donate!)
12/31/16 Top Brain Tumor News Stories for 2016
2016 was an exciting year - but I think 2017 will be the year we see big steps forward!
Happy New Year!
BTW: The copay program will open again very soon - maybe Monday or Tuesday. Will announce it as soon as it opens!
12/31/16 Florescent light helps surgeons target brain tumors
This is approved and a standard treatment in Europe. It is not yet approved in the USA so it is only available in clinical trials. Hopefully the new administration will relax some FDA rules and allow potentially life saving treatments to be approved sooner rather than later.
12/31/16 Pathway linked to slower aging also fuels brain cancer
They need to find a way to target only the tumor cells and not have the side effects on the normal cells. There is a lot of research going on to accomplish this with other treatments, such as antibody drug conjugates, convection enhanced delivery, super selective intraarterial intracranial infusion, gene therapies such as used by Tocagen and a few others.
12/25/16 Some glioblastoma patients benefit from 'ineffective' treatment, Stanford researchers say
This is the problem with clinical trials.. if the average patients doesn't benefit, they call it a failure. They do not identify the patients who do benefit. In this case, they identified a group of patients who would benefit from Avastin, even though an average patient doesn't. I have seen many patients with a huge benefit from it, which makes no sense when you look at the trial results. This may explain why. They should go back to the original Avastion trials, and see if this group of patients did better,
Displaying Stories 1 to 20 of 6086